

DAFTAR PUSTAKA

- Ahmed T Toosy., Deborah F Mason., David H Miller., 2014. Optic neuritis. www.thelancet.com/neurology.
- Akman, A., 2018. Optical coherence tomography: basics and technical aspects. In *Optical Coherence Tomography in Glaucoma* (pp. 7-12). Springer, Cham.
- Agarwal, A. ed., 2015. *Manual of Neuro-ophthalmology*. JP Medical Ltd.
- Badan POM RI., 2015. Antituberkulosis. Pusta informasi Obat Nasional dan Badan Pengawas obat dan Makanan. Available at : <http://pionas.pom.go.id/ioni/bab-5-infeksi/52-tuberkulosis-dan-leprosi/521-antituberkulosis>.
- Barton, J.J. and Benatar, M., 2003. *Field of vision: A manual and atlas of perimetry*. Springer Science & Business Media.
- Barton J., Sexton B., 2008. *Examination of The Visual Field. Alberts and Jacobiec's Principles and Practice of Ophthalmology Third Edition'*. Saunders. Elsevier.
- Becker, D.A., Balcer, L.J. and Galetta, S.L., 2012. The neurological complications of nutritional deficiency following bariatric surgery. *Journal of obesity*, 2012.
- Behbehani, R.S., Affel, E.L., Sergott, R.C. and Savino, P.J., 2005. Multifocal ERG in ethambutol associated visual loss. *British journal of ophthalmology*, 89(8), pp.976-982.
- Bobrowitz, I.D., 1966. Ethambutol in the retreatment of pulmonary tuberculosis. *Annals of the New York Academy of Sciences*, 135(2), pp.796-822.
- Brancato, R. and Lumbroso, B., 2004. *Guide to optical coherence tomography interpretation*. INC Innovation-News Communication.
- Castro, D. P. E., Kawase, J., & Melo Jr, L. A. S. (2008). Learning effect of standard automated perimetry in healthy individuals. *Arquivos brasileiros de oftalmologia*, 71, 523-528.
- Chai, S. J., & Foroozan, R. 2007. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. *British journal of ophthalmology*, 91(7), 895-897.

Chamberlain, P.D., Sadaka, A., Berry, S. and Lee, A.G., 2017. Ethambutol optic neuropathy. *Current opinion in ophthalmology*, 28(6), pp.545-551.

Chan, R.Y.C. and Kwok, A.K.H., 2006. Ocular toxicity of ethambutol. *Hong Kong Medical Journal*, 12(1), p.56.

Chan, E. W. E., Liao, J., Foo, R. C. M., Loon, S. C., Aung, T., Wong, T. Y., & Cheng, C. Y. 2013. Diagnostic performance of the ISNT rule for glaucoma based on the Heidelberg retinal tomograph. *Translational vision science & technology*, 2(5), 2-2.

Chen, S.C., Lin, M.C. and Sheu, S.J., 2015. Incidence and prognostic factor of ethambutol-related optic neuropathy: 10-year experience in southern Taiwan. *The Kaohsiung journal of medical sciences*, 31(7), pp.358-362.

Chung, H., Yoon, Y.H., Hwang, J.J., Cho, K.S., Koh, J.Y. and Kim, J.G., 2009. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. *Toxicology and applied pharmacology*, 235(2), pp.163-170.

De Palma, P., Franco, F., Bragliani, G., Michetti, L., Marescotti, A., Pirazzoli, G. and Fiorenza, M., 1989. The incidence of optic neuropathy in 84 patients treated with ethambutol. *Metabolic, pediatric, and systemic ophthalmology (New York, NY: 1985)*, 12(1-3), pp.80-82.

Detoraki, M. and Moschos, M.M., 2016. The role of multifocal electroretinography in the assessment of drug-induced retinopathy: a review of the literature. *Ophthalmic research*, 56(4), pp.169-177.

Ezer, N., Benedetti, A., Darvish-Zargar, M. and Menzies, D., 2013. Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. *The International journal of tuberculosis and lung disease*, 17(4), pp.447-455.

Galetta, K.M., Calabresi, P.A., Frohman, E.M. and Balcer, L.J., 2011. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. *Neurotherapeutics*, 8(1), pp.117-132

Gharagozloo, M., 2015. Clinical study Immune-mediated cochleovestibular disease, 116(5), pp. 296–301.

Gong, H. and Amemiya, T., 2001. Optic nerve changes in zinc-deficient rats. *Experimental eye research*, 72(4), pp.363-369.

Goukon, H., Hirasawa, K., Kasahara, M., Matsumura, K. and Shoji, N., 2019. Comparison of Humphrey Field Analyzer and imo visual field test results in patients with glaucoma and pseudo-fixation loss. *Plos one*, 14(11), p.e0224711.

Grecescu, M., 2014. Optical coherence tomography versus visual evoked potentials in detecting subclinical visual impairment in multiple sclerosis. *Journal of medicine and life*, 7(4), p.538.

Grzybowski, A., Zülsdorff, M., Wilhelm, H., & Tonagel, F. (2015). Toxic optic neuropathies: an updated review. *Acta ophthalmologica*, 93(5), 402-410.

Griffith, D.E., Brown-Elliott, B.A., Shepherd, S., McLarty, J., Griffith, L. and Wallace Jr, R.J., 2005. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. *American journal of respiratory and critical care medicine*, 172(2), pp.250-253

Gümüş, A. and Öner, V., 2015. Follow up of retinal nerve fiber layer thickness with optic coherence tomography in patients receiving anti-tubercular treatment may reveal early optic neuropathy. *Cutaneous and ocular toxicology*, 34(3), pp.212-216

Han, J., Byun, M.K., Lee, J., Han, S.Y., Lee, J.B. and Han, S.H., 2015. Longitudinal analysis of retinal nerve fiber layer and ganglion cell–inner plexiform layer thickness in ethambutol-induced optic neuropathy. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 253(12), pp.2293-2299.

Hassounah, I.A., Shehata, N.A., Kimsawatde, G.C., Hudson, A.G., Sriranganathan, N., Joseph, E.G. and Mahajan, R.L., 2016. Designing and testing single tablet for tuberculosis treatment through electrospinning. In *Fabrication and Self-Assembly of Nanobiomaterials* (pp. 335-365). William Andrew Publishing.

Heifets, L. B., 1994. Seminars in Respiratory Infections. In *Antimycobacterial drugs*, 9(2), pp. 84–103.

Holder, G.E., 2004. Electrophysiological assessment of optic nerve disease. *Eye*, 18(11), pp.1133-1143.

Hood, D.C., Bach, M., Brigell, M., Keating, D., Kondo, M., Lyons, J.S., Marmor, M.F., McCulloch, D.L. and Palmowski-Wolfe, A.M., 2012. ISCEV standard for clinical multifocal electroretinography (mfERG)(2011 edition). *Documenta Ophthalmologica*, 124(1), pp.1-13.

Indonesia, P. D. P.2021. Tuberkulosis: pedoman diagnosis dan penatalaksanaan di Indonesia. *Jakarta: Indah Offset Citra Grafika*.

Jin, K. W., Lee, J. Y., Rhiu, S., & Choi, D. G. 2019. Longitudinal evaluation of visual function and structure for detection of subclinical Ethambutol-induced optic neuropathy. *PloS one*, 14(4), e0215297.

Kahook, M.Y., Noecker, R.J. and Today, G., 2007. How do you interpret a 24-2 Humphrey Visual Field printout. *Glaucoma Today*, 57.

Kandel, H., Adhikari, P., Shrestha, G.S., Ruokonen, E.L. and Shah, D.N., 2012. Visual function in patients on ethambutol therapy for tuberculosis. *Journal of ocular pharmacology and therapeutics*, 28(2), pp.174-178.

Kanski, Jack., Menon., Jay., 2003. *Neuro-ophthalmology in Clinical Ophthalmology*.ed, pp.596-609. Toronto. Butterworth Heinemann.

Kardon, R.H., Morrissey, M.C. and Lee, A.G., 2006, January. Abnormal multifocal electroretinogram (mfERG) in ethambutol toxicity. In *Seminars in ophthalmology* (Vol. 21, No. 4, pp. 215-222). Taylor & Francis.

Kass, I., Mandel, W. and Cohen, H., 2015 *Though Shifted*, pp. 4–7.

Kementerian Kesehatan RI., 2018. InfoDatin Tuberculosis. Kementerian Kesehatan RI. Available at:<https://www.depkes.go.id/article/view/18030500005/waspadaipeningkatanpenyakitmenular.html%0Ahttp://www.depkes.go.id/article/view/17070700004/program-indonesia-sehat-dengan-pendekatan-keluarga.html>.

Kementerian Kesehatan RI., 2020. Profil Kesehatan Indonesia tahun 2019. Kementerian Kesehatan RI, p.153. Available at: <https://pusdatin.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Profil-Kesehatan-indonesia-2019.pdf>.

Kemenkes, R. I. 2020. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberculosis*. Jakarta: Kementerian Kesehatan RI.

Kim, K.L. and Park, S.P., 2016. Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level. *Cutaneous and ocular toxicology*, 35(3), pp.228-232.

Kim, Y.K. and Hwang, J.M., 2009. Serial retinal nerve fiber layer changes in patients with toxic optic neuropathy associated with antituberculosis pharmacotherapy. *Journal of ocular pharmacology and therapeutics*, 25(6), pp.531-536.

- Kinoshita, J., Iwata, N., Maejima, T., Kimotsuki, T. and Yasuda, M., 2012. Retinal function and morphology in monkeys with ethambutol-induced optic neuropathy. *Investigative ophthalmology & visual science*, 53(11), pp.7052-7062.
- Kolar, R., Tornow, R.P., Laemmer, R., Odstrcilik, J., Mayer, M.A., Gazarek, J., Jan, J., Kubena, T. and Cernosek, P., 2013. Analysis of visual appearance of retinal nerve fibers in high resolution fundus images: a study on normal subjects. *Computational and mathematical methods in medicine*, 2013.
- Koul, P.A., 2015. Ocular toxicity with ethambutol therapy: Timely recaution. *Lung India: Official Organ of Indian Chest Society*, 32(1), p.1.
- Kozak, S.F., Inderlied, C.B., Hsu, H.Y., Heller, K.B. and Sadun, A.A., 1998. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. *Diagnostic microbiology and infectious disease*, 30(2), pp.83-87.
- Kulkarni, H.S., Keskar, V.S., Bavdekar, S.B. and Gabhale, Y., 2010. Bilateral optic neuritis due to isoniazid (INH). *Indian pediatrics*, 47(6), pp.533-535.
- Kumar, A., Sandramouli, S., Verma, L., Tewari, H.K. and Khosla, P.K., 1993. Ocular ethambutol toxicity: is it reversible?. *Journal of clinical neuro-ophthalmology*, 13(1), pp.15-17.
- Kumar, A. and Dada, T., 1999. Visual evoked response (VER) in ocular ethambutol toxicity. *The National medical journal of India*, 12(4), pp.193-194
- Lai, T.Y.Y., Ngai, J.W.S., Lai, R.Y.K. and Lam, D.S.C., 2009. Multifocal electroretinography changes in patients on ethambutol therapy. *Eye*, 23(8), pp.1707-1713.
- Lamirel, C., Newman, N.J. and Biousse, V., 2010. Optical coherence tomography (OCT) in optic neuritis and multiple sclerosis. *Revue neurologique*, 166(12), pp.978-986.
- Lee, J.Y., Han, J., Seo, J.G., Park, K.A. and Oh, S.Y., 2019. Diagnostic value of ganglion cell-inner plexiform layer for early detection of ethambutol-induced optic neuropathy. *British Journal of Ophthalmology*, 103(3), pp.379-384.
- Leibold, J.E., 1966. The ocular toxicity of ethambutol and its relation to dose. *Annals of the New York Academy of Sciences*, 135(2), pp.904-909.

- Leopold, I.H., 1978. Zinc deficiency and visual impairment?. *Am J Ophthalmol*, 85, pp.871-875.
- Levin, L.A., Kaufman, P.L. and Alm, A. eds., 2011. *Adler's Physiology of the Eye*
- Liu, G.T., 2001. Visual loss: optic neuropathies. *Neuro-ophthalmology, diagnosis and management*.
- Liu, Y., Dinkin, M.J., Loewenstein, J.I., Rizzo III, J.F. and Cestari, D.M., 2008. Multifocal electroretinographic abnormalities in ethambutol-induced visual loss. *Journal of Neuro-ophthalmology*, 28(4), pp.278-282.
- Lodha, R., 2014. Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: A randomized controlled trial. *American Journal of Clinical Nutrition*, 100(5), pp. 1287–1297.
- Louis B., Cantor MD., Christopher J., Rapuano MD., Colin A., McCannel., 2019. *American academy of ophthalmology sec 10 Glaucoma. Chapter 3 Clinical Evaluation*
- Ma, Z., Ginsberg, A.M. and Spigelman, M., 2007. Antimycobacterium agents.
- Menon, V., Jain, D., Saxena, R. and Sood, R., 2009. Prospective evaluation of visual function for early detection of ethambutol toxicity. *British journal of ophthalmology*, 93(9), pp.1251-1254.
- Morgan, J.E., 2004. Circulation and axonal transport in the optic nerve. *Eye*, 18(11), pp.1089-1095.
- Naismith, R.T., Tutlam, N.T., Xu, J., Shepherd, J.B., Klawiter, E.C., Song, S.K. and Cross, A.H., 2009. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. *Neurology*, 73(1), pp.46-52.
- Nazari, M.A., Kobarfard, F., Tabarsi, P. and Salamzadeh, J., 2009. Serum copper (cu) alterations in pulmonary tuberculosis patients under treatment with ethambutol. *Biological trace element research*, 128(2), pp.161-166.
- Newman SA., Arnold AC., Friedman DI., Kline LB., Rizzo III JF., 2018 *BCSC : Neuro-opthamology*. AAO.
- Pengantar, K., 2012. Anti-Tuberculosis. *Current Bioactive Compounds*, 2(1), pp. 105–105.

Pardianto, G., Moeloek, N., Reveny, J., Wage, S., Satari, I., Sembiring, R. and Srisamran, N., 2013. Retinal thickness changes after phacoemulsification. *Clinical ophthalmology (Auckland, NZ)*, 7, p.2207.

Park, S., Siegelman., 2013. *The Anatomy and Cell Biology of The Human Retina in Duane's Clinical Ophthalmology*, on CD ROM, Lippincott and William Wilkins.

Perhimpunan Dokter Paru Indonesia., 2011. Pengobatan tuberkulosis. Dalam: *Tuberkulosis: pedoman diagnosis dan penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia, pp.20-30.

Pineles, S.L., Wilson, C.A., Balcer, L.J., Slater, R. and Galetta, S.L., 2010. Combined optic neuropathy and myelopathy secondary to copper deficiency. *Survey of ophthalmology*, 55(4), pp.386-392.

PK Mukherjee MS., 2010. *Blood Supply of the Optic Nerve. ,Essentials of Neuro-ophthalmology*. India.

Rasool, Mahmood, Arif Malik, Abdul Manan, Khuram Aziz, Amna Mahmood, Saima Zaheer, Naveed Shuja, Mahmood Husain Qazi, Mohammad Amjad Kamal, and Sajjad Karim. "Determination of potential role of antioxidative status and circulating biochemical markers in the pathogenesis of ethambutol induced toxic optic neuropathy among diabetic and non-diabetic patients." *Saudi journal of biological sciences* 22, no. 6 (2015): 739-743.

Referano, Agustiawan., 2011. *Retina dari Pediatrik hingga Geriatrik 3D OCT vs 2D OCT*. Jakarta Eye Center: Jakarta

Sadun, A.A. and Wang, M.Y., 2008. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year.

Salmon, J.F. and Kanski, J.J., 2004. *Glaucoma: a colour manual of diagnosis and treatment*. Butterworth-Heinemann Medical.

Schiefer, U., Hart, W., 2007. *Clinical Neuro Ophthalmology : Functional Anatomy of The Human Visual Pathway*. St.Louis. USA.

Sharma, P. and Sharma, R., 2011. Toxic optic neuropathy. *Indian journal of ophthalmology*, 59(2), p.137.

Shuba, ML., Young, HK., 2008. *Glaucomatous Visual Field Loss*. *Alberts and Jacobiec's Principles and Practice of Ophthalmology Third Edition* . Saunders Elsevier.

- Song, W. and Si, S., 2017. The rare ethambutol-induced optic neuropathy: a case-report and literature review. *Medicine*, 96(2).
- Sood, D., Khumar, P., 2009. *Basic Perimetry. Diagnostic Procedures in Ophthalmology Second Edition*. Jaypee Brothers Medical Publisher LTD.
- Srivastava, A.K., Goel, U.C., Bajaj, S., Singh, K.J., Dwivedi, N.C. and Tandon, M.P., 1997. Visual evoked responses in ethambutol induced optic neuritis. *The Journal of the Association of Physicians of India*, 45(11), pp.847-849.
- Sung, K.R., Kim, D.Y., Park, S.B. and Kook, M.S., 2009. Comparison of retinal nerve fiber layer thickness measured by Cirrus HD and Stratus optical coherence tomography. *Ophthalmology*, 116(7), pp.1264-1270.
- Surabaya, D.K., 2015. *Profil Kesehatan Kota Surabaya Tahun 2015*. Surabaya: Dinas Kesehatan Kota Surabaya.
- Sutter, E.E. and Tran, D., 1992. The field topography of ERG components in man—I. The photopic luminance response. *Vision research*, 32(3), pp.433-446.
- Tang, W. W., Lai, J. S., Tham, C. C., Chan, K. K., & Chan, K. S. 2006. Scanning laser polarimetry in pulmonary tuberculosis patients on chemotherapy. *ANNALS-ACADEMY OF MEDICINE SINGAPORE*, 35(6), 395.
- Takayama, K. and Kilburn, J.O., 1989. Inhibition of synthesis of arabinogalactan by ethambutol in *Mycobacterium smegmatis*. *Antimicrobial agents and chemotherapy*, 33(9), pp.1493-1499.
- TSAI, R.K. and LEE, Y.H., 1997. Reversibility of ethambutol optic neuropathy. *Journal of ocular pharmacology and therapeutics*, 13(5), pp.473-477.
- Vale, J, R., 1975. Treatment of tuberculosis. *Tidsskrift for den Norske Laegeforening*, 95(34–36), pp. 1991–1992.
- Vaughan, D. and Asbury, T., 2007. *Vaughan & Asbury's general ophthalmology*. McGraw-Hill Medical.
- Wang, M.Y. and Sadun, A.A., 2013. Drug-related mitochondrial optic neuropathies. *Journal of Neuro-Ophthalmology*, 33(2), pp.172-178.

Weinstein, J.M., 1987. Adler's Physiology of the Eye (Clinical Application). American Journal of Ophthalmology, 104(1), p.99.

World Health Organization and Stop TB Initiative (World Health Organization), 2019. Treatment of tuberculosis: guidelines. World Health Organization.

World Health Organization., 2021. Global Tuberculosis Report 2021. *World Health Organization*, pp. 5-9.

WOUNG, L.C., JOU, J.R. and LIAW, S.L., 1995. Visual function in recovered ethambutol optic neuropathy. Journal of ocular pharmacology and therapeutics, 11(3), pp.411-419.

Wu, L., Teodoros, E., 2010. Medical Retina Focus Retinal on imaging, Springer, pp.1-10.

Yamada, D., Saiki, S., Furuya, N., Ishikawa, K.I., Imamichi, Y., Kambe, T., Fujimura, T., Ueno, T., Koike, M., Sumiyoshi, K. and Hattori, N., 2016. Ethambutol neutralizes lysosomes and causes lysosomal zinc accumulation. Biochemical and biophysical research communications, 471(1), pp.109-116.

Yang, H.K., Park, M.J., Lee, J.H., Lee, C.T., Park, J.S. and Hwang, J.M., 2016. Incidence of toxic optic neuropathy with low-dose ethambutol. The International Journal of Tuberculosis and Lung Disease, 20(2), pp.261-264.

Yenice, Ö., & Temel, A. 2005. Evaluation of two Humphrey perimetry programs: full threshold and SITA standard testing strategy for learning effect. *European journal of ophthalmology*, 15(2), 209-212.

Yoon, Y.H., Jung, K.H., Sadun, A.A., Shin, H.C. and Koh, J.Y., 2000. Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicology and applied pharmacology, 162(2), pp.107-114.

Yudapratwi, N., 2011 . Perbandingan densitas sel ganglion retina dengan dan tanpa suplementasi zinc pada tikus yang diberi etambutol. Tesis. Bandung: Universitas Padjajaran.

Zoumalan, C.I., Agarwal, M. and Sadun, A.A., 2005. Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 243(5), pp.410-416.

Zumla, A.I., Gillespie, S.H., Hoelscher, M., Philips, P.P., Cole, S.T., Abubakar, I., McHugh, T.D., Schito, M., Maeurer, M. and Nunn, A.J., 2014. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. *The Lancet infectious diseases*, 14(4), pp.327-340.

LAMPIRAN



REKOMENDASI PERSETUJUAN ETIK

Nomor : 500/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 11 Agustus 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21060381	No Sponsor Protokol	
Peneliti Utama	dr. Fachria Jumiah	Sponsor	
Judul Peneliti	Pengaruh terapi etambutol terhadap perubahan ketebalan lapisan serabut saraf retina peripapil ditinjau dari gambaran OCT dan dibandingkan dengan pemeriksaan perimetri		
No Versi Protokol	1	Tanggal Versi	17 Juni 2021
No Versi PSP	1	Tanggal Versi	17 Juni 2021
Tempat Penelitian	RSUD Labuang Baji dan Balai Besar Kesehatan Paru Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 11 Agustus 2021 sampai 11 Agustus 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amendemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapo SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

FORMULIR PERSETUJUAN

Saya yang bertanda tangan di bawah ini :

Nama :

Umur : tahun

Alamat :

Telepon/HP :

Menyatakan bersedia untuk berpartisipasi pada penelitian ini yang berjudul :

“PENGARUH TERAPI ETAMIBUTOL TERHADAP PERUBAHAN KETEBALAN LAPISAN SERABUT SARAF RETINA PERIPAPIL DITINJAU DARI GAMBARAN OCT DAN DIBANDINGKAN DENGAN PEMERIKSAAN PERIMETRI“

Setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan dan manfaat yang akan didapatkan pada penelitian ini, khususnya bagi kemajuan ilmu kedokteran.

Makassar,

Saksi I

Saksi II

(.....)

(.....)

Penanggung jawab penelitian :

dr. Fachria Jumiah
Griya Bakti Utama
Kota Makassar
Telp. 085298553030

Penanggung jawab medik :

Dr. dr. Yunita, Sp.M(K), M.Kes
Perumahan Citra Garden Blok L1 No.1 Cluster Golden Tulip
Kabupaten Gowa
Telp. 08152541665

DISETUJUI OLEH KOMISI PENELITIAN
KESEHATAN FAKULTAS KEDOKTERAN UNHAS
TGL.....2021

NO	OCT RNFL (1 BULAN)						OCT RNFL (2 BULAN)						HUMPHREY (0 BULAN)						HUMPHREY (1 BULAN)														
	Temporal			Superior			Nasal			Inferior			Temporal			Superior			Nasal			Inferior			PSD			MD			PSD		
	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS	OD	OS	OS
1	90	76	134	133	61	76	145	151	89	90	139	134	69	70	142	150	1.07	1.51	1.35	1.09	1.52	0.44	1.13	1.55									
2	92	97	132	119	54	60	137	117	100	93	120	122	55	72	147	121	1.05	0.16	1.37	1.33	0.03	-1.58	1.73	2.87									
3	88	81	125	137	76	81	142	138	94	85	122	127	72	69	117	133	0.01	-0.85	1.67	1.96	0.13	-0.51	1.8	1.64									
4	83	72	161	160	95	97	181	194	82	71	153	163	91	93	184	195	-1.88	-1.45	1.24	1.24	-0.84	-0.05	1.86	1.51									
5	97	105	162	161	89	76	164	144	92	96	164	158	88	96	161	156	1.79	2.1	1.36	1.59	1.75	1.35	1.2	1.11									
6	70	73	133	148	94	90	149	147	75	80	135	128	100	98	142	148	-1.17	2.2	1.71	1.42	2.13	2	1.35	1.62									
7	83	79	147	139	89	88	174	164	80	80	151	152	95	79	189	178	1.82	1.3	1.37	1.49	2.44	1.9	1.38	1.4									
8	98	88	160	147	59	59	120	147	88	85	141	142	66	74	137	142	-0.22	-1.35	1.53	2.04	1.19	-1.56	1.41	1.67									
9	91	105	121	121	74	91	104	104	76	62	105	129	71	85	119	109	1.22	1.49	1.21	1.15	2.16	0.93	0.99	1.24									
10	89	76	118	123	70	77	160	158	89	79	125	130	75	80	159	162	1.5	1.53	1.54	1.66	1.46	1.74	1.22	1.34									
11	77	65	146	125	81	77	147	163	72	68	153	125	84	72	156	163	0.07	1.46	2.21	1.35	-0.31	-1.13	1.8	1.75									
12	71	68	145	154	93	92	149	142	89	74	126	153	105	87	136	138	-0.11	0.28	1.4	1.78	1.34	-0.29	1.91	1.98									
13	76	79	133	140	90	87	150	142	80	85	121	119	85	89	149	152	0.11	1.16	1.82	1.4	-2.05	0.37	2.81	1.55									
14	74	74	124	121	103	70	145	144	74	80	126	120	104	66	145	149	1.03	-0.22	1.94	1.16	1.29	1.41	1.23	1.41									
15	70	78	121	126	89	74	134	131	72	74	110	118	87	79	140	132	-0.09	0.08	1.72	2.15	0.05	1.64	2.21	1.35									
16	81	170	159	159	93	84	159	154	85	77	172	172	92	87	151	157	-2.31	0.09	2.07	1.46	1.11	-0.16	1.37	1.27									
17	88	98	162	160	98	76	163	158	88	95	158	160	99	84	163	157	-2.47	0.85	2.5	1.43	-1.52	0.75	1.39	1.53									
18	80	80	135	131	87	80	133	132	76	79	135	132	86	88	135	133	2.63	1.73	1.16	1.25	1.6	0.01	1.26	1.5									
19	81	68	157	146	123	125	184	171	82	70	166	130	124	126	170	172	0.9	0.18	1.34	1.68	1.13	0.43	1.52	1.52									

NO	HUMPHREY (2 BULAN)					
	MD		OS		PSD	
	OD	OS	OD	OS	OD	OS
1	1.19	0.31	1.33	1.25		
2	0.06	1.56	1.3	1.67		
3	2.01	1.45	1.25	1.04		
4	-0.5	-0.85	1.43	1.97		
5	0.51	-0.63	1.28	1.71		
6	2.34	2.13	1.2	1.33		
7						
8	0.75	0.54	1.69	1.17		
9	1.23	0.3	1.48	1.97		
10	2.13	1.05	1.05	1.54		
11	1.53	1.37	1.65	1.21		
12	-0.83	-0.27	3.07	1.93		
13	0.88	-0.54	1.62	1.74		
14	0.79	0.7	1.6	1.48		
15	2.34	1.44	1.33	0.97		
16	0.73	1.75	1.76	1.6		
17	-0.79	-0.79	1.85	1.85		
18	-0.88	-1.83	1.25	1.63		
19	0.85	1.31	1.71	1.34		
20	-1.53	-1.37	1.57	1.77		
21						
22						

OUTPUT DATA ANALISIS

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
Usia	19	19	52	26.63	9.679
Valid N (listwise)	19				

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TOD_0	38	9	18	13.24	2.211
TOD_1	38	10	17	13.05	1.999
TOD_2	38	10	17	12.87	1.727
Temp_OD_0	38	61	131	86.45	15.495
Sup_OD_0	38	103	180	139.03	17.987
Nasal_OD_0	38	56	140	87.16	16.559
Infe_OD_0	38	108	182	145.87	19.238
Temp_OD_1	38	65	105	81.39	9.857
Sup_OD_1	38	105	170	140.00	16.310
Nasal_OD_1	38	54	125	83.63	15.452
Infe_OD_1	38	104	194	148.45	19.550
Temp_OD_2	38	62	100	81.74	8.711
Sup_OD_2	38	105	172	137.79	17.975
Nasal_OD_2	38	55	126	85.32	15.021
Infe_OD_2	38	109	195	149.45	19.547
MD_OD_0	38	-2.47	2.63	.4526	1.27079
PSD_OD_0	38	1.09	2.50	1.5563	.33644
MD_OD_1	38	-2.05	2.44	.5868	1.19134
PSD_OD_1	38	.99	2.87	1.5626	.40101
MD_OD_2	38	-1.83	2.34	.5379	1.15276
PSD_OD_2	38	.97	3.07	1.5418	.37030
Valid N (listwise)	38				

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TOD_0	.109	38	.200*	.965	38	.268
TOD_1	.174	38	.005	.933	38	.024
TOD_2	.219	38	.000	.916	38	.008
Temp_OD_0	.146	38	.039	.912	38	.005
Sup_OD_0	.123	38	.155	.965	38	.279
Nasal_OD_0	.122	38	.163	.951	38	.097
Infe_OD_0	.089	38	.200*	.973	38	.492
Temp_OD_1	.121	38	.172	.961	38	.204
Sup_OD_1	.115	38	.200*	.952	38	.105
Nasal_OD_1	.099	38	.200*	.949	38	.081
Infe_OD_1	.108	38	.200*	.976	38	.573
Temp_OD_2	.105	38	.200*	.986	38	.919
Sup_OD_2	.141	38	.054	.943	38	.053
Nasal_OD_2	.087	38	.200*	.955	38	.130
Infe_OD_2	.086	38	.200*	.986	38	.919
MD_OD_0	.123	38	.158	.949	38	.084
PSD_OD_0	.146	38	.039	.925	38	.014
MD_OD_1	.143	38	.047	.947	38	.072
PSD_OD_1	.170	38	.007	.844	38	.000
MD_OD_2	.109	38	.200*	.956	38	.141
PSD_OD_2	.111	38	.200*	.862	38	.000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test Statistics^a

	T O D	T O D	T O D	Tem p_O D_1	Tem p_O D_2	Tem p_O D_2	Sup _O D_1	Sup _O D_2	Sup _O D_2	Nas al_O D_1	Nas al_O D_2	Nas al_O D_2	Infe _O D_1	Infe _O D_2	Infe _O D_2	MD _O D_1	MD _O D_2	MD _O D_2	PS D_ OD	PS D_ OD	PS D_ OD
	- 1	- 2	- 2	- D_1	- D_2	- D_2	- D_1	- D_2	- D_2	- D_1	- D_2	- D_2	1- Infe	2- Infe	2- Infe	1- MD	2- MD	2- MD	-1- PS	-2- PS	-2- PS
	D 0	D 0	D 1	Tem p_O D_0	Tem p_O D_0	Tem p_O D_1	Sup _O D_0	Sup _O D_0	Sup _O D_1	Nas al_O D_0	Nas al_O D_0	Nas al_O D_1	_O D_0	_O D_0	_O D_1	_O D_0	_O D_0	_O D_1	D_ OD	D_ OD	D_ OD
Z	.636 ^b	1.485 ^b	.933 ^b	2.975 ^b	1.857 ^b	.796 ^c	.106 ^b	.951 ^b	1.052 ^b	2.235 ^b	.861 ^b	1.264 ^c	1.110 ^c	1.240 ^c	1.141 ^c	.558 ^c	.399 ^c	.268 ^b	.094 ^b	.181 ^c	.044 ^b
Asymp. Sig. (2-tailed)	.525	.138	.351	.003	.063	.426	.916	.342	.293	.025	.389	.206	.267	.215	.254	.577	.690	.788	.925	.856	.965

- a. Wilcoxon Signed Ranks Test
- b. Based on positive ranks.
- c. Based on negative ranks.

Nonparametric Correlations

Correlations

	T O D	T O D	T O D	Tem p_O D_0	Su p_O D_0	Nas al_O D_0	Infe _O D_0	Tem p_O D_1	Su p_O D_1	Nas al_O D_1	Infe _O D_1	Tem p_O D_2	Su p_O D_2	Nas al_O D_2	Infe _O D_2	M D_ O D_0	PS D_ OD	M D_ O D_1	PS D_ OD	M D_ O D_2	PS D_ OD
	- 0	- 1	- 2	- D_0	- D_0	- D_0	- D_0	- D_1	- D_1	- D_1	- D_1	- D_2	- D_2	- D_2	- D_2	- D_0	- D_0	- D_1	- D_1	- D_2	- D_2
Spearman's rho	.000	.611	.717	-.094	.037	.141	.397	-.062	.010	.185	.426**	-.234	.245	.150	.428**	.047	-.231	.051	-.390	-.149	.107
Sig. (2-tailed)	.000	.000	.000	.575	.823	.397	.014	.711	.955	.267	.008	.157	.138	.370	.007	.778	.163	.762	.016	.374	.523
N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
TO D_1	.611	1.000	.505	-.123	.068	.235	.112	-.051	.209	.274	.301	-.046	.388	.273	.251	.182	-.195	.298	-.379	-.024	-.094

	Sig. (2-tailed)	.000	.000	.000	.462	.683	.156	.502	.761	.208	.097	.067	.785	.016	.097	.128	.274	.241	.070	.019	.888	.573
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
TO D_2	Correlation Coefficient	.717	.585	1.000	-.013	.127	.230	.343	-.068	.177	.255	.402	-.200	.339	.155	.346	-.088	-.084	-.062	-.252	-.269	.151
	Sig. (2-tailed)	.000	.000	.938	.446	.164	.035	.686	.289	.122	.012	.228	.037	.354	.033	.599	.616	.712	.127	.102	.367	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Temp O D_0	Correlation Coefficient	-.094	-.123	-.001	1.000	-.073	-.266	-.283	.756**	.220	-.311	-.023	.574**	.119	-.257	.073	-.046	-.078	-.110	-.100	-.116	-.140
	Sig. (2-tailed)	.575	.462	.938	.663	.107	.085	.000	.184	.057	.891	.000	.477	.119	.664	.784	.641	.510	.550	.487	.401	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Sup O D_0	Correlation Coefficient	.037	.068	.127	-.073	1.000	.245	.442**	-.034	.716**	.301	.492**	.083	.646**	.351	.537**	-.099	.185	-.165	.071	-.684**	.372
	Sig. (2-tailed)	.823	.633	.436	.663	.138	.005	.839	.000	.066	.002	.621	.000	.031	.001	.556	.267	.321	.673	.000	.021	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Nasal OD _0	Correlation Coefficient	.141	.235	.230	-.266	.245	1.000	.331	-.411	.357	.818**	.475**	-.345	.245	.838**	.362	-.140	.138	-.050	.038	-.272	.187
	Sig. (2-tailed)	.397	.156	.164	.107	.138	.042	.010	.028	.000	.003	.034	.138	.000	.026	.404	.407	.767	.819	.099	.261	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

Infe_O D_0	Correlati on Co effi cie nt	.397	.112	.343	-.283	.442*	.331*	1.000	-.369	.279	.392	.748**	-.239	.342	.336	.705**	-.190	.148	-.033	.077	-.311	.202
	Sig. (2- tail ed)	.014	.502	.035	.085	.005	.042	.	.023	.090	.015	.000	.149	.036	.039	.000	.252	.375	.842	.645	.057	.225
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Tem_p O D_1	Correlati on Co effi cie nt	-.062	-.051	-.068	.756**	-.034	-.411*	-.369	1.000	.155	-.492**	-.171	.673**	.187	-.328	-.080	.096	-.105	-.002	-.280	-.027	-.172
	Sig. (2- tail ed)	.711	.761	.686	.000	.839	.010	.023	.	.354	.002	.305	.000	.262	.044	.635	.565	.531	.990	.088	.874	.301
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Sup O D_1	Correlati on Co effi cie nt	.010	.209	.107	.220	.716**	.357*	.279	.155	1.000	.378*	.503**	.233	.822**	.456**	.484**	-.232	.198	-.112	.004	-.671**	.284
	Sig. (2- tail ed)	.955	.208	.289	.184	.000	.028	.090	.354	.	.019	.001	.159	.000	.004	.002	.161	.233	.503	.979	.000	.084
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Nas al_ OD _1	Correlati on Co effi cie nt	.185	.274	.205	-.311	.301	.818**	.392*	-.492**	.378*	1.000	.496**	-.433**	.348*	.849**	.352*	-.173	.136	-.024	.053	-.292	.118
	Sig. (2- tail ed)	.267	.097	.172	.057	.066	.000	.015	.002	.019	.	.002	.007	.032	.000	.030	.299	.417	.888	.752	.075	.481
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Infe O D_1	Correlati on Co effi cie nt	.426	.301	.400	-.023	.492**	.475**	.748**	-.171	.503**	.496**	1.000	.008	.567**	.450**	.892**	-.084	.043	.009	-.010	-.547**	.168
	Sig. (2- tail ed)																					

	Sig. (2-tailed)	.008	.067	.012	.891	.002	.003	.000	.305	.001	.002	.	.960	.000	.005	.000	.614	.797	.955	.952	.000	.313
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Temp_OD_2	Correlation Coefficient	.234	-.046	.200	.574**	.083	-.345*	-.239	.673**	.233	-.433**	.008	1.000	.101	-.248	-.038	.027	-.051	-.002	.045	-.028	-.283
	Sig. (2-tailed)	.157	.785	.228	.000	.621	.034	.149	.000	.159	.007	.960	.	.545	.133	.821	.870	.761	.991	.789	.867	.085
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Sup_OD_2	Correlation Coefficient	.245	.388	.339	.119	.646**	.245	.342*	.187	.822**	.348*	.567**	.101	1.000	.386*	.521**	-.099	.063	-.037	-.216	-.650**	.293
	Sig. (2-tailed)	.138	.016	.037	.477	.000	.138	.036	.262	.000	.032	.000	.545	.	.017	.001	.553	.706	.827	.193	.000	.075
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Nasal_OD_2	Correlation Coefficient	.150	.273	.155	-.257	.351*	.838**	.336*	-.328*	.456**	.849**	.450**	-.248	.386*	1.000	.351*	-.014	.172	.112	-.075	-.279	.263
	Sig. (2-tailed)	.370	.079	.354	.119	.031	.000	.039	.044	.004	.005	.133	.017	.	.031	.932	.303	.503	.653	.083	.089	.110
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Infe_OD_2	Correlation Coefficient	.428*	.251	.346*	.073	.537**	.362*	.705**	-.080	.484**	.352*	.892**	-.038	.521**	.351*	1.000	.051	.001	.000	-.085	-.619**	.190
	Sig. (2-tailed)	.007	.128	.033	.664	.001	.026	.000	.635	.002	.030	.000	.821	.001	.031	.	.763	.995	.999	.611	.000	.252
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

MD _O D_0	Co rrel ati on Co effi cie nt	.04	.18	-.08	-.04	-.09	-.14	-.19	-.06	.09	-.23	-.17	-.08	.02	-.09	-.01	.05	1.00	-.42	-.47	-.37	-.16	-.09
	Sig. (2- tail ed)	.77	.24	.59	.78	.55	.40	.25	.56	.16	.29	.61	.87	.55	.93	.76	.	.00	.00	.02	.31	.57	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
PS D_0 _0	Co rrel ati on Co effi cie nt	-.23	-.15	-.08	-.07	.18	.13	.14	-.10	.19	.13	.04	-.05	.06	.17	.00	-.42	1.00	-.19	.12	-.05	-.17	
	Sig. (2- tail ed)	.16	.23	.61	.64	.26	.40	.37	.53	.23	.41	.79	.76	.70	.30	.99	.00	.	.24	.44	.75	.28	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	
MD _O D_1	Co rrel ati on Co effi cie nt	.05	.29	-.06	.11	.16	.05	.03	-.00	-.11	.02	.09	.00	.03	.11	.00	.47	1.00	-.19	-.66	-.41	-.37	
	Sig. (2- tail ed)	.76	.07	.71	.51	.32	.76	.84	.99	.50	.88	.95	.99	.82	.50	.99	.00	.24	.	.00	.00	.01	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	
PS D_1 _1	Co rrel ati on Co effi cie nt	-.39	-.37	-.25	.10	.07	.03	.07	-.28	.00	.05	-.01	.04	-.21	.07	.08	.37	.12	-.66	1.00	-.18	.22	
	Sig. (2- tail ed)	.11	.11	.12	.55	.67	.81	.64	.08	.97	.75	.95	.78	.19	.65	.61	.02	.44	.00	.	.25	.16	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	
MD _O D_2	Co rrel ati on Co effi cie nt	.14	.02	.26	.11	.68	.27	.31	.02	.67	.29	.54	.02	.65	.27	.61	.16	-.05	-.41	-.18	1.00	-.52	
	Sig. (2- tail ed)	.44	.94	.06	.11	.44	.27	.31	.97	.11	.29	.77	.98	.00	.09	.61	.08	.05	.88	.18	.00	.52	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	

	Sig. (2-tailed)	.374	.888	.102	.487	.000	.099	.057	.874	.000	.075	.000	.867	.000	.089	.000	.313	.754	.009	.259	.	.001
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
PS D_ OD _2	Correlation Coefficient	.107	-.094	.151	-.140	.372	.187	.202	-.172	.284	.118	.168	-.283	.293	.263	.190	-.095	.177	-.379	.228	-.528**	1.000
	Sig. (2-tailed)	.523	.573	.367	.401	.021	.261	.225	.301	.084	.481	.313	.085	.075	.110	.252	.570	.289	.019	.168	.001	.
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

**
Correlation is significant at the 0.01 level (2-tailed)

*
Correlation is significant at the 0.05 level (2-tailed)

.

Correlations

		TO D_0	TO D_1	TO D_2	Temp_0	Su p_0	Nas al_0	Inf e_0	Temp_1	Su p_1	Nas al_1	Inf e_1	Temp_2	Su p_2	Nas al_2	Inf e_2	M D_0	PS D_0	M D_1	PS D_1	M D_2	PS D_2
TO D_0	Pe ars on Co rrel ati on	1	.596*	.702*	-.109	.063	.254	.415**	-.131	.084	.280	.483**	-.258	.289	.185	.475**	-.068	-.197	.077	-.402*	-.213	-.061
	Sig .(2- tail ed)		.000	.000	.515	.707	.124	.010	.433	.616	.089	.002	.118	.078	.267	.003	.687	.236	.644	.012	.200	.717
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
TO D_1	Pe ars on Co rrel ati on	.596*	1	.6336*	-.080	.177	.242	.168	-.092	.249	.325*	.335*	-.066	.404*	.259	.263	.074	-.208	.331*	-.385*	-.069	-.144
	Sig .(2- tail ed)	.000	.000	.000	.632	.289	.143	.313	.584	.131	.046	.040	.694	.012	.117	.111	.660	.211	.043	.017	.678	.388
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
TO D_2	Pe ars on Co rrel ati on	.702*	.6336*	1	-.108	.214	.321*	.397*	-.164	.257	.321*	.395*	-.209	.391*	.228	.320*	-.186	-.019	-.011	-.270	-.360*	.206
	Sig .(2- tail ed)	.000	.000	.000	.519	.197	.049	.014	.326	.119	.049	.014	.208	.015	.169	.050	.263	.908	.946	.101	.027	.215
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Temp_0	Pe ars on Co rrel ati on	-.109	-.080	-.080	1	-.019	-.158	-.338*	.777**	.284	-.269	.030	.610**	.247	-.202	.096	.028	-.074	-.038	-.073	-.218	-.059
	Sig .(2- tail ed)	.515	.631	.519		.911	.345	.038	.000	.084	.102	.857	.000	.135	.224	.567	.867	.659	.822	.665	.188	.723
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

Sup _O D_ 0	Pe ars on Co rrel ati on	. 0 6 3	. 1 7 7	. 2 1 4	- .01 9	1	.16 6	.38 3*	.01 6	.71 9**	.23 7	.42 1**	.09 9	.72 6**	.32 2*	.43 7**	- .18 6	.25 3	- .10 4	- .07 3	- .62 7**	.36 4*
	Sig . (2- tail ed)	. 7 0 7	. 2 8 9	. 1 9 7	.91 1		.31 8	.01 8	.92 6	.00 0	.15 1	.00 8	.55 6	.00 0	.04 9	.00 6	.26 4	.12 6	.53 4	.66 3	.00 0	.02 5
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Nas al_ OD_ 0	Pe ars on Co rrel ati on	. 2 5 4	. 2 4 2	. 3 2 1*	- .15 8	.16 6	1	.37 3*	- .39 5*	.36 4*	.82 7**	.53 8**	- .39 2*	.24 6	.82 5**	.40 3*	- .20 9	.17 1	.00 1	- .08 9	- .34 4*	.12 7
	Sig . (2- tail ed)	. 1 2 4	. 1 4 3	. 0 4 9	.34 5	.31 8		.02 1	.01 4	.02 5	.00 0	.00 1	.01 5	.13 6	.00 0	.01 2	.20 9	.30 3	.99 6	.59 4	.03 4	.44 8
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Infe _O D_ 0	Pe ars on Co rrel ati on	. 4 1 5*	. 1 6 8	. 3 9 7	- .33 8*	.38 3*	.37 3*	1	- .43 3**	.31 9	.38 6*	.74 7**	- .22 2	.36 5*	.36 0*	.72 4**	- .26 1	.18 4	- .08 9	- .00 3	- .35 2*	.30 5
	Sig . (2- tail ed)	. 0 1 0	. 3 1 3	. 0 1 4	.03 8	.01 8	.02 1		.00 7	.05 1	.01 7	.00 0	.18 0	.02 4	.02 6	.00 0	.11 3	.26 8	.59 5	.98 6	.03 0	.06 3
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Tem p_ O D_ 1	Pe ars on Co rrel ati on	- .1 3 1	- .0 9 2	- .1 6 4	.77 7**	.01 6	- .39 5*	- .43 3**	1	.16 7	- .48 8**	- .25 8	.66 2**	.20 3	- .31 7	- .15 4	.10 8	- .07 5	.01 8	- .15 9	- .03 7	- .13 3
	Sig . (2- tail ed)	. 4 3 3	. 5 8 4	. 3 2 6	.00 0	.92 6	.01 4	.00 7		.31 7	.00 2	.11 8	.00 0	.22 3	.05 2	.35 5	.52 0	.65 5	.91 7	.34 0	.82 6	.42 5
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

Sup _O D_ 1	Pe ars on Co rrel ati on28	.71	.36	.31	.16	1	.32	.55	.23	.86	.41	.51	-	.19	-	-	-	.29	
		0	2	2	4	9**	4*	9	7		5*	2**	0	5**	8**	1**	.34	7*	8	.09	.10	.69	5**
	Sig . (2- tail ed)08	.00	.02	.05	.31		.04	.00	.16	.00	.00	.00	.03	.23	.55	.54	.00	.07	
		6	1	1	4	0	5	1	7		6	0	5	0	9	1	3	3	5	5	0	4	
	N	3	3	3	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Nas al_ OD _1	Pe ars on Co rrel ati on	.	.	.	-	.23	.82	.38	-	.32	1	.50	-	.30	.90	.38	-	.10	.08	-	-	.08	
		2	3	3	.26	7	7**	6*	.48	5*		5**	.45	0	0**	2*	.12	9	1	.05	.34	9*	
	Sig . (2- tail ed)10	.15	.00	.01	.00	.04		.00	.00	.06	.00	.01	.45	.51	.62	.76	.03	.62	
		0	0	0	2	1	0	7	2	6		1	4	7	0	8	2	5	9	8	2	3	
	N	3	3	3	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Infe _O D_ 1	Pe ars on Co rrel ati on03	.42	.53	.74	-	.55	.50	1	.02	.58	.47	.89	-	.04	-	-	-	.17	
		4	3	3	0	1**	8**	7**	.25	2**	5**		0	7**	4**	3**	.22	8	9	.04	.05	.55	9**
	Sig . (2- tail ed)85	.00	.00	.00	.11	.00	.00		.90	.00	.00	.00	.16	.76	.77	.75	.00	.29	
		0	0	0	7	8	1	0	8	0	1		3	0	3	0	8	8	1	9	0	8	
	N	3	3	3	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Tem p_ O D_ 2	Pe ars on Co rrel ati on	-	-	-	.61	.09	-	-	.66	.23	-	.02	1	.11	-	-	.00	-	-	.07	-	-	
		2	0	2	0**	9	.39	.22	2**	0	.45	0		9	.30	.05	.00	.03	.03	.02	.03	.28	
	Sig . (2- tail ed)00	.55	.01	.18	.00	.16	.00	.90		.47	.06	.75	.95	.82	.84	.66	.82	.08	
		1	6	2	0	6	5	0	0	5	4	3		8	6	4	5	5	6	8	9	2	
	N	3	3	3	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

Sup _O D_ 2	Pe ars on Co rrel ati on	. 2 8 9	. 4 0 4*	. 3 9 1*	.24 7	.72 6**	.24 6	.36 5*	.20 3	.86 5**	.30 0	.58 7**	.11 9	1	.35 3*	.55 8**	-. 23 9	.12 4	-. 01 0	-. 24 7	-. 69 4**	.32 6*
	Sig . (2- tail ed)	. 0 7 8	. 0 1 2	. 0 1 5	.13 5	.00 0	.13 6	.02 4	.22 3	.00 0	.06 7	.00 0	.47 8		.03 0	.00 0	.14 8	.45 9	.95 3	.13 4	.00 0	.04 6
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Nas al_ OD _2	Pe ars on Co rrel ati on	. 1 8 5	. 2 5 9	. 2 2 8	-. 20 2	.32 2*	.82 5**	.36 0*	-. 31 7	.41 8**	.90 0**	.47 4**	-. 30 2	.35 3*	1	.35 1*	-. 07 5	.14 6	.14 2	-. 07 6	-. 35 2*	.19 2
	Sig . (2- tail ed)	. 2 6 7	. 1 1 7	. 1 6 9	.22 4	.04 9	.00 0	.02 6	.05 2	.00 9	.00 0	.00 3	.06 6	.03 0		.03 1	.65 4	.38 1	.39 4	.65 0	.03 0	.24 9
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
Infe _O D_ 2	Pe ars on Co rrel ati on	. 4 7 5*	. 2 6 3	. 2 2 0*	.09 6	.43 7**	.40 3*	.72 4**	-. 15 4	.51 1**	.38 2*	.89 3**	-. 05 3	.55 8**	.35 1*	1	-. 09 8	-. 02 2	.01 5	-. 13 5	-. 55 7**	.19 7
	Sig . (2- tail ed)	. 0 0 3	. 1 1 1	. 0 5 0	.56 7	.00 6	.01 2	.00 0	.35 5	.00 1	.01 8	.00 0	.75 4	.00 0	.03 1		.55 9	.89 8	.92 8	.41 7	.00 0	.23 7
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
MD _O D_ 0	Pe ars on Co rrel ati on	-. 0 6 8	. 0 7 4	-. 1 1 8	.02 8	-. 18 6	-. 20 9	-. 26 1	.10 8	-. 34 7*	-. 12 6	-. 22 8	.00 9	-. 23 9	-. 07 5	-. 09 8	1	-. 52 9**	.46 7**	-. 24 3	.23 7	-. 11 4
	Sig . (2- tail ed)	. 6 8 7	. 6 6 0	. 2 6 3	.86 7	.26 4	.20 9	.11 3	.52 0	.03 3	.45 2	.16 8	.95 5	.14 8	.65 4	.55 9		.00 1	.00 3	.14 1	.15 1	.49 7
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

PS D_ OD _0	Pearson Correlation	-.074	-.074	-.074	.253	.171	.184	-.075	.198	.109	.049	-.037	.124	.146	-.022	-.529**	1	-.293	.098	-.094	.279	
	Sig. (2-tailed)	.236	.236	.236	.009	.126	.033	.005	.023	.005	.008	.825	.049	.031	.898	.001		.074	.058	.057	.090	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
MD O D_ 1	Pearson Correlation	.071*	.031	-.031	-.038	.104	.009	-.018	.099	.081	-.049	-.033	-.010	.142	.015	.467**	-.293	1	-.681**	.346*	-.313	
	Sig. (2-tailed)	.044	.094	.094	.022	.034	.006	.005	.007	.009	.077	.086	.093	.039	.028	.003	.074		.000	.034	.056	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
PS D_ OD _1	Pearson Correlation	.025*	.087	-.020	-.073	.073	.089	-.159	.101	-.050	.051	.072	-.247	-.076	.135	-.243	.098	-.681**	1	-.043	.237	
	Sig. (2-tailed)	.011	.007	.011	.005	.003	.006	.000	.005	.008	.008	.008	.004	.000	.007	.001	.008	.000		.008	.015	
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
MD O D_ 2	Pearson Correlation	.036	.096	-.030*	.218	.627**	.344*	.352*	.037	.695**	.349*	.559**	.036	.694**	.352*	.557**	.237	-.094	.346*	-.043	1	-.505**
	Sig. (2-tailed)	.008	.007	.008	.000	.000	.000	.000	.006	.000	.002	.000	.009	.000	.000	.000	.015	.057	.034	.079		.001
	N	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

PS D_ OD _2	Pe ars on Co rrel ati on	. 0 6 1	-. 1 4 4	. 2 0 6	-. 05 9	.36 4*	.12 7	.30 5	-. 13 3	.29 3	.08 2	.17 3	-. 28 5	.32 6*	.19 2	.19 7	-. 11 4	.27 9	-. 31 3	.23 7	-. 50 5**	1
	Sig . (2- tail ed)	. 7 1 7	. 3 8 8	. 2 1 5	.72 3	.02 5	.44 8	.06 3	.42 5	.07 4	.62 3	.29 8	.08 2	.04 6	.24 9	.23 7	.49 7	.09 0	.05 6	.15 3	.00 1	
	N	3 8	3 8	3 8	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38

**.
Cor
rela
tion
is
sig
nific
ant
at
the
0.0
1
lev
el
(2-
tail
ed).
*.
Cor
rela
tion
is
sig
nific
ant
at
the
0.0
5
lev
el
(2-
tail
ed).